摘要
目的:为我国罕见病医疗保障和用药法规的建立提供借鉴和参考。方法:介绍和分析不同国家和地区对罕见病及其药物开发的政策。结果:各主要发达国家在药品注册方面和管理方面都有一套相关政策.包括对孤儿药的认定及其开发研究的鼓励政策,值得我国在孤儿药品注册和药品管理政策制定时借鉴和参考。结论:明确罕见病的定义.制定激励措施对罕见病的研究进展有很大的推动作用。
Objective: To provide the reference for establishing the policy of rare disease and orphan drugs in China. Methods: Analyzing incentive measures for the development of orphan drugs in different countries and regions. Results: The major developed countries have a set of related policies in the medical registration and management aspects, including the identification of orphan drugs and its development policy, it is worth of learning.Conclusions: Definiting the rare diseases and making incentive measures can encourage the research and development of rare diseases.
出处
《药品评价》
CAS
2010年第22期48-51,共4页
Drug Evaluation
关键词
罕见病
孤儿药
政策
激励措施
Rare Diseases
Orphan Drugs
Policy
Incentive Measures